Novolin 70/30 — Competitive Intelligence Brief

Novolin 70/30 (Novolin 70/30) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin combination (intermediate-acting and short-acting). Area: Diabetes.

marketed Insulin combination (intermediate-acting and short-acting) Insulin receptor Diabetes Biologic

Target snapshot

Novolin 70/30 (Novolin 70/30) — Wockhardt. Novolin 70/30 is a fixed-ratio insulin combination that replaces or supplements the body's natural insulin to regulate blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Novolin 70/30 TARGET	Novolin 70/30	Wockhardt	marketed	Insulin combination (intermediate-acting and short-acting)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin combination (intermediate-acting and short-acting) class)

1. Wockhardt · 1 drug in this class